NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial.
HCC
NMR
SIRT
interventional therapy
lipid profiles
metabolomics
overall survival
radiofrequency ablation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Jun 2021
03 Jun 2021
Historique:
received:
02
05
2021
revised:
25
05
2021
accepted:
31
05
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
This exploratory study aimed to evaluate lipidomic and metabolomic profiles in patients with early and advanced HCCs and to investigate whether certain metabolic parameters may predict the overall survival in these patients. A total of 60 patients from the prospective, randomized-controlled, multicenter phase II SORAMIC trial were included in this substudy; among them were 30 patients with an early HCC who underwent radiofrequency ablation combined with sorafenib or a placebo and 30 patients with an advanced HCC who were treated with a selective internal radiation therapy (SIRT) plus sorafenib vs. sorafenib alone. The blood serum of these patients was analyzed using a standardized nuclear magnetic resonance (NMR) platform. All tested metabolites were correlated with the overall survival. The overall survival (OS) was significantly higher in patients with an early HCC (median OS: 34.0 months) compared with patients with an advanced HCC (median OS: 12.0 months) ( NMR-based lipidomic and metabolomic profiling has the potential to identify individual metabolite biomarkers that predict the outcome of patients with an HCC exposed to non-invasive therapeutic management.
Sections du résumé
BACKGROUND
BACKGROUND
This exploratory study aimed to evaluate lipidomic and metabolomic profiles in patients with early and advanced HCCs and to investigate whether certain metabolic parameters may predict the overall survival in these patients.
METHODS
METHODS
A total of 60 patients from the prospective, randomized-controlled, multicenter phase II SORAMIC trial were included in this substudy; among them were 30 patients with an early HCC who underwent radiofrequency ablation combined with sorafenib or a placebo and 30 patients with an advanced HCC who were treated with a selective internal radiation therapy (SIRT) plus sorafenib vs. sorafenib alone. The blood serum of these patients was analyzed using a standardized nuclear magnetic resonance (NMR) platform. All tested metabolites were correlated with the overall survival.
RESULTS
RESULTS
The overall survival (OS) was significantly higher in patients with an early HCC (median OS: 34.0 months) compared with patients with an advanced HCC (median OS: 12.0 months) (
CONCLUSIONS
CONCLUSIONS
NMR-based lipidomic and metabolomic profiling has the potential to identify individual metabolite biomarkers that predict the outcome of patients with an HCC exposed to non-invasive therapeutic management.
Identifiants
pubmed: 34205110
pii: cancers13112787
doi: 10.3390/cancers13112787
pmc: PMC8199928
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ther Apher Dial. 2019 Oct;23(5):467-473
pubmed: 30663261
Circulation. 2014 Feb 4;129(5):553-61
pubmed: 24345402
Am J Epidemiol. 2009 Dec 1;170(11):1415-21
pubmed: 19889709
Chromosoma. 2008 Feb;117(1):1-13
pubmed: 17943301
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1526-31
pubmed: 16896044
Eur J Prev Cardiol. 2016 Mar;23(5):502-10
pubmed: 25956428
Metabolomics. 2018 Aug 30;14(9):116
pubmed: 30830387
J Lipid Res. 2019 Sep;60(9):1516-1534
pubmed: 31239285
J Cancer. 2016 Mar 20;7(6):626-32
pubmed: 27076843
PLoS One. 2013;8(1):e54242
pubmed: 23372693
J Nutr. 2003 Nov;133(11 Suppl 1):3778S-3784S
pubmed: 14608114
Can J Gastroenterol Hepatol. 2021 Feb 18;2021:8813410
pubmed: 33681091
EBioMedicine. 2019 Oct;48:505-512
pubmed: 31648995
Cancer Lett. 2017 Aug 10;401:39-45
pubmed: 28527945
Exp Cell Res. 2016 Jul 1;345(1):37-50
pubmed: 27237097
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
J Nutr. 1997 Jul;127(7):1412-21
pubmed: 9202100
Int J Cancer. 2017 Sep 15;141(6):1148-1160
pubmed: 28577304
Endocr Connect. 2017 Nov;6(8):647-658
pubmed: 29042448
Horm Metab Res. 2016 Sep;48(10):630-637
pubmed: 27589345
Hepatology. 2013 Jul;58(1):229-38
pubmed: 23463346
Clin Gastroenterol Hepatol. 2015 Feb;13(2):237-45
pubmed: 24275343
Diagnostics (Basel). 2021 Feb 03;11(2):
pubmed: 33546466
Int J Endocrinol. 2016;2016:5616807
pubmed: 27795708
J Clin Lipidol. 2007 Dec;1(6):583-92
pubmed: 19657464
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):244-50
pubmed: 14734476
Cancer Manag Res. 2018 Apr 11;10:715-734
pubmed: 29692630
Lipids Health Dis. 2006 Mar 03;5:4
pubmed: 16515689
Cancer Prev Res (Phila). 2016 Dec;9(12):906-914
pubmed: 27658890
Lipids Health Dis. 2017 Mar 1;16(1):51
pubmed: 28249586
Biomed Res Int. 2013;2013:681027
pubmed: 24260743
Sci Rep. 2016 Apr 14;6:24430
pubmed: 27075403
Neurology. 2020 Mar 17;94(11):e1147-e1156
pubmed: 31919113
Metabolomics. 2016;12:146
pubmed: 27616976
Mol Cancer. 2010 Aug 12;9:215
pubmed: 20704698
Angew Chem Int Ed Engl. 2016 Jan 26;55(5):1614-50
pubmed: 26694856
Nutrients. 2020 Nov 03;12(11):
pubmed: 33153126
Hepatology. 2017 Aug;66(2):432-448
pubmed: 28073184
Transl Psychiatry. 2020 May 13;10(1):148
pubmed: 32404908
World J Gastroenterol. 2003 Mar;9(3):385-91
pubmed: 12632482
Front Physiol. 2017 Jul 18;8:480
pubmed: 28769812
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1402-10
pubmed: 25973024
Clin Chim Acta. 2019 Mar;490:81-87
pubmed: 30578754
Sci Rep. 2017 Mar 15;7:44692
pubmed: 28294182
Cancer Cytopathol. 2019 Nov;127(11):691-699
pubmed: 31518056
Urol Oncol. 2011 Sep-Oct;29(5):551-7
pubmed: 21930086
Liver Int. 2015 Feb;35(2):620-6
pubmed: 24930619
Carcinogenesis. 2001 May;22(5):795-804
pubmed: 11323400
Int J Cancer. 2009 Dec 1;125(11):2679-86
pubmed: 19544528
Cell Rep. 2014 Feb 27;6(4):646-56
pubmed: 24529702
Lipids Health Dis. 2015 Sep 24;14:117
pubmed: 26403989
Arch Intern Med. 1997 Apr 14;157(7):792-6
pubmed: 9125012
J Clin Med. 2020 Jun 12;9(6):
pubmed: 32545708
Biochim Biophys Acta. 1997 Sep 4;1348(1-2):179-86
pubmed: 9370331
Hepatology. 2013 May;57(5):2072-7
pubmed: 23150189
Surgery. 2014 Feb;155(2):263-70
pubmed: 24569301
Gut. 2009 Jun;58(6):777-89
pubmed: 19201776